SCHEMBL1243883

SCHEMBL1243883

CCOC(=O)/C=C/[C@@H]1COC(C)(C)O1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.45
TDP1 Q9NUW8 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
NPSR1 Q6W5P4 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.34
MAPT P10636 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CA2 P00918 2/20 0.33
LMNA P02545 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
TTR P02766 1/20 0.31
DPP4 P27487 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3988831 1.00 L3MBTL1 (0.45) L3MBTL1TDP1HCAR2NPSR1CTDSP1
SCHEMBL12150587 1.00 L3MBTL1 (0.45) L3MBTL1TDP1HCAR2NPSR1CTDSP1
SCHEMBL4426142 1.00 L3MBTL1 (0.45) L3MBTL1TDP1HCAR2NPSR1CTDSP1
SCHEMBL3988833 1.00 L3MBTL1 (0.45) L3MBTL1TDP1HCAR2NPSR1CTDSP1
SCHEMBL4425298 1.00 L3MBTL1 (0.45) L3MBTL1TDP1HCAR2NPSR1CTDSP1
SCHEMBL9914107 1.00 L3MBTL1 (0.45) L3MBTL1TDP1HCAR2NPSR1CTDSP1
SCHEMBL3988829 1.00 L3MBTL1 (0.45) L3MBTL1TDP1HCAR2NPSR1CTDSP1
SCHEMBL4422593 1.00 L3MBTL1 (0.45) L3MBTL1TDP1HCAR2NPSR1CTDSP1
SCHEMBL15355842 0.85 L3MBTL1 (0.43) L3MBTL1TDP1HCAR2NPSR1CTDSP1
SCHEMBL9812980 0.84 MAPT (0.38) L3MBTL1MAPTCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180370982-A1 PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM MSN LABORATORIES PRIVATE LIMITED (IN) 2018-12-27 US claimed
EP-3313847-A1 PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM MSN Laboratories Private Limited (IN) 2018-05-02 EP claimed
WO-2016207907-A1 PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM MSN LABORATORIES PRIVATE LIMITED (IN) 2016-12-29 WO claimed
US-10633390-B2 Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form MSN LABORATORIES PRIVATE LIMITED (IN) 2020-04-28 US disclosed
US-20190077797-A1 PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES EMORY UNIVERSITY 2019-03-14 US disclosed
US-20180370982-A1 PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM MSN LABORATORIES PRIVATE LIMITED (IN) 2018-12-27 US disclosed
EP-3313847-A1 PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM MSN Laboratories Private Limited (IN) 2018-05-02 EP disclosed
WO-2017075590-A2 PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES COCRYSTAL PHARMA, INC. (US) 2017-05-04 WO disclosed
WO-2016207907-A1 PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM MSN LABORATORIES PRIVATE LIMITED (IN) 2016-12-29 WO disclosed
EP-1732931-B1 METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL JANSSEN SCIENCES IRELAND UC (IE) 2016-05-18 EP disclosed
EP-2522367-B1 Oligomer-protease inhibitor conjugates NEKTAR THERAPEUTICS (US) 2016-01-20 EP disclosed
WO-2008112286-A2 DE NOVO SYNTHESIS OF CONJUGATES NEKTAR THERAPEUTICS (US) 2008-09-18 WO disclosed
WO-2008112289-A2 OLIGOMER-PROTEASE INHIBITOR CONJUGATES NEKTAR THERAPEUTICS (US) 2008-09-18 WO disclosed
US-20070208184-A1 METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL Janssen Sciences Ireland Unlimited Company (IE) 2007-09-06 US disclosed
EP-1732931-A1 METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL Tibotec Pharmaceuticals Ltd. (IE) 2006-12-20 EP disclosed
WO-2005095410-A1 METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-10-13 WO disclosed
US-5665746-A BACTERICIDE HOFFMANN-LA ROCHE INC. (US) 1997-09-09 US disclosed
US-5594135-A BACTERICIDES HOFFMANN-LA ROCHE INC. (US) 1997-01-14 US disclosed
US-5589473-A BACTERICIDES HOFFMANN-LA ROCHE INC. (US) 1996-12-31 US disclosed
EP-0675122-A2 Mono or bicyclic DNA gyrase inhibitors F. HOFFMANN-LA ROCHE AG (CH) 1995-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077797-A1 PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES DERA, DPYD, DUS2 L3MBTL1 2700/4885TDP1 666/4885HCAR2 2358/4885
US-10633390-B2 Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form FFAR1, CYP2S1, CYP1B1 L3MBTL1 4385/4885TDP1 1052/4885HCAR2 38/4885
US-20070208184-A1 METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL HTR3C, UGT1A3, HTR3D L3MBTL1 4520/4885TDP1 4205/4885HCAR2 633/4885
US-20180370982-A1 PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM FFAR1, CYP2S1, FFAR3 L3MBTL1 4347/4885TDP1 910/4885HCAR2 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.